
ECHO 4 PWS: Orthopedics
When: Tuesday, December 17, 2024 at 5:00 PM EST
Where: Virtual/Zoom Video
This series is for healthcare providers only
PWSA | USA's - ECHO 4 PWS Healthcare Provider Series
PWSA | USA launched our new Healthcare Provider Project ECHO Series, ECHO 4 PWS, in 2023. We are proud to offer this opportunity to healthcare professionals who work with patients affected by Prader-Willi syndrome (PWS) and to be the first PWS organization to implement Project ECHO® in the United States.
Our next healthcare ECHO topic will take place on Tuesday, December 17, 2024, at 5:00 p.m. EST and will focus on Orthopedics and PWS presented by Dr. Harold van Bosse, followed by a 20-minute case study on PWS.
PWSA | USA’s Healthcare Provider Project ECHO Series will touch on a wide range of healthcare topics in the PWS space and will be available for all health professionals across our network including (but not limited to): Geneticists, Pediatric Endocrinologists, Neonatologists, Nurses, Pediatricians, Endocrinologists, Psychiatrists, Psychologists, Social Workers, Occupational Therapists, Pulmonologists, Orthopedic Surgeons, Dieticians, Physiotherapists, Speech and Language Therapists, Medical Students and Professional Caregivers.
While this ECHO series is only for healthcare providers to attend, recordings of the webinars are available for our PWS families to view HERE.
Scroll below to find more ECHO 4 PWS webinar opportunities.
Speaker

Harold van Bosse, MD
ECHO 4 PWS is Sponsored By

LEarn More about PWS Research
Soleno Therapeutics to Invest $5 Million in Research Toward a Potential Cure for Prader-Willi Syndrome
PWSA | USA is excited to celebrate a powerful new commitment from Soleno Therapeutics, a company already making history in the Prader-Willi syndrome (PWS) community. Following the FDA approval of VYKAT™ XR (diazoxide choline extended-release tablets), the first-ever treatment for hyperphagia in PWS, Soleno has announced plans to invest up to $5 million in grant […]
HERO Clinical Trial for ARD-101 Now Enrolling Open-Label Extension (OLE)
Earlier this year, Aardvark Therapeutics launched HERO, a global Phase 3 clinical trial investigating ARD-101, an innovative, orally administered treatment designed to help reduce hyperphagia (excessive hunger) and food-seeking behaviors in individuals with Prader-Willi syndrome (PWS). All patients who have completed treatment on the AVK-101-301 study through Week 12/End of Treatment will have the option to join […]
Acadia Shares Results of Phase 3 Carbetocin Trial: Primary Endpoint Not Met
On Wednesday, September 24, 2025, Acadia Pharmaceuticals shared an update on their Phase 3 COMPASS PWS trial, which evaluated intranasal carbetocin (ACP-101) for hyperphagia (excessive hunger) in children and adults with Prader-Willi syndrome (PWS). The trial did not meet its primary endpoint of improving scores on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) from baseline […]